One-shot vaccine breakthrough for Britain
A SINGLE-SHOT vaccine from Johnson & Johnson is 66 per cent effective against Covid-19, it was announced yesterday.
World trials of the vaccine showed protection against severe disease was even higher at 85 per cent.
Crucially, no one who received the jab was admitted to hospital or died.
The news is another huge victory for the UK Vaccines Taskforce, which has secured access to 30 million doses and the option of buying a further 22 million.
It came just hours after Novavax announced its coronavirus vaccine – of which the UK has ordered 60 million doses. It is 89 per cent effective at stopping infection and 86 per cent effective against the new Kent variant of the virus.
More than 43,000 people from eight countries and three regions took part in trials of the single-shot vaccine from Johnson & Johnson, which was developed by its pharmaceutical arm Janssen.
Deliveries of the Janssen jab could begin arriving in Britain in the second half of the year, provided it receives the green light from regulators.
Dr Paul Stoffels, Johnson & Johnson’s chief scientific officer, said the jab could significantly ease the burden on health services across the world, particularly as only one dose is required.
Dr Stoffels said: “A one-shot vaccine is considered by the World Health Organisation to be the best option in pandemic settings, enhancing access, distribution and compliance.
“Eighty-five per cent efficacy in preventing severe Covid-19 disease and prevention of Covid19-related medical interventions will potentially protect hundreds of millions of people from serious and fatal outcomes.”
Britain’s vaccine rollout is continuing at pace – almost 8.4 million doses have been dished out so far.
Government figures yesterday showed that the total included 7.9 million first doses and 478,000 second doses.
Dr Stoffels said his firm was aiming to produce more than one billion doses of the vaccine during 2021 at a number of plants around the world including the US, Europe, India and Africa.
It has also already started developing booster vaccines to tackle variants in case they are needed.
Johnson & Johnson plans to apply for regulatory approval in the US next week, followed shortly by applications in Europe and the UK.
In the United States arm of the trial, the level of protection against moderate to severe Covid infection was found to be 72 per cent. It was 66 per cent in Latin America and 57 per cent in the South Africa, where a mutant strain of the virus has been dominating.
The overall efficacy from the combined trials was 66 per cent, which is lower than estimates for the Oxford, Pfizer and
Moderna vaccines. But scientists warned yesterday that headline figures for different vaccines could not be compared directly.
Professor Saul Faust, director of the Southampton NIHR Wellcome Trust Clinical Research Facility, which is helping Janssen with trials, said: “It’s apples and oranges. The key thing is what happens when you deploy in a population and on one dose this vaccine is going to stop people going into hospital and death.”
Prof Faust is a chief investigator for the UK arm of the next trial, to see whether two doses can offer better immunity.
Experts welcomed the findings and said the Janssen vaccine’s easy fridge storage and single dose regimen could make a huge difference in the fight to end the pandemic.
Kevin Marsh, professor of tropical medicine at Oxford University, said: “The real headline result is that a single-shot vaccine, capable of easy long-term storage and administration, provided complete protection against hospitalisation and death.
“This is important because the immediate requirement of vaccination globally is to limit deaths as quickly as possible. These results are especially encouraging for Africa and low-tomiddle-income countries globally where the combination of single-shot, ease of storage and protection against multiple variants is critical.”
Dr Michael Head, senior research fellow in global health at Southampton University, said: “We do need to vaccinate the world and there’s about eight billion people out there. So the chance to have multiple vaccines available is
excellent and a single-dose product has advantages in terms of cost and logistics for a large-scale rollout.”
Prof Sheila Bird of Cambridge University said: “Huge congratulations to Kate Bingham and her UK committee of experts who made the critical sub-selection of seven from over 200 vaccine contenders. Their magnificent seven include the top five to date.”